Collavant®n2:A SCIENTIFICALLY PROVEN TYPE II NATIVE COLLAGEN
Collagen, the most abundant protein in the body, is one of the main components of connective tissue such as tendons, ligaments, skin and cartilage. Collagen is best known for its structural role: it ensures the cohesion of the various tissues, gives them elasticity, strength and flexibility, and allows them to regenerate.
Among the 28 types of collagen that have been identified, type II collagen is the main structural protein of cartilage.
As type II collagen is a naturally occurring substance in the body, it is a safe and well-tolerated molecule.
MODE OF ACTION
Joint disorders are characterised by an autoimmune component that induces an immune system response directed against the type II collagen present in the body: as the products of collagen degradation are identified as potentially dangerous by the immune cells, an immune response is triggered against the collagen, resulting in inflammation and cartilage degradation, which further damages the joints. This phenomenon repeats itself in a loop and creates a vicious circle that is difficult to break.
Studies show that supplementation with native (undenatured) type II collagen can help modulate the immune response against endogenous type II collagen, thereby promoting joint health.1,2
Native type II collagen works through a mechanism of action called "Oral Tolerance", which consists of a decrease in the immune response to a previously ingested antigen.
The process takes place in 4 phases:
- Type II native collagen enters Peyer's patches, located in the small intestine
- It deactivates the T-cell attack against endogenous type II collagen
- A weaker immunological response is induced
- Collagen destruction is reduced.
The collagen used in PHYSIOMANCE Collagen Articulation is Collavant®n2 type II collagen with proven effectiveness in improving joint health.
A first study in rats with induced osteoarthritis showed a significant reduction in joint pain3.
The same study also showed a reduction in inflammatory response: Collavant®n2 significantly reduced plasma IL-1β levels compared to placebo3.
According to a second clinical study carried out on 39 patients with knee osteoarthritis and randomly divided into two groups, one treated with 1500 mg/day of paracetamol and the other treated with 1500 mg/day of paracetamol + 10 mg/day of type II native collagen4, a reduction in knee discomfort was observed after 3 months of supplementation.
According to the same study, there was a significant improvement in knee function after 3 months of paracetamol + collagen supplementation, compared to paracetamol alone.
In conclusion, Collavant®n2 reduces joint discomfort3-4, reduces inflammation3 and improves knee function4.
1. Stuart, J. M., A. S. Townes, et A. H. Kang. « Nature and Specificity of the Immune Response to Collagen in Type II Collagen-Induced Arthritis in Mice ». The Journal of Clinical Investigation 69, no 3 (mars 1982): 673‑83. https://doi.org/10.1172/jci110495.
2. Park, Kyung-Su, Min-Jung Park, Mi-La Cho, Seung-Ki Kwok, Ji Hyeon Ju, Hyeok-Jae Ko, Sung-Hwan Park, et Ho-Youn Kim. « Type II Collagen Oral Tolerance; Mechanism and Role in Collagen-Induced Arthritis and Rheumatoid Arthritis ». Modern Rheumatology 19, no 6 (2009): 581‑89. https://doi.org/10.1007/s10165-009-0210-0.
3. Mannelli, L. D. C. et al. BMC Musculoskelet. Disord. 2013,14, 228
4. Bakilan, F. et al. Eurasian J. Med. 2016, 48: 95–101
Collavant®n2 is a trademark licensed by BIOIBERICA SAU.